Modern radiopharmaceuticals for lung cancer imaging with positron emission tomography/computed tomography scan: A systematic review.
Positron emission tomography/computed tomography
lung cancer
radiopharmaceuticals
Journal
SAGE open medicine
ISSN: 2050-3121
Titre abrégé: SAGE Open Med
Pays: England
ID NLM: 101624744
Informations de publication
Date de publication:
2020
2020
Historique:
received:
09
09
2019
accepted:
27
08
2020
entrez:
16
10
2020
pubmed:
17
10
2020
medline:
17
10
2020
Statut:
epublish
Résumé
In this study, we evaluated the use and the contribution of radiopharmaceuticals to the field of lung neoplasms imaging using positron emission tomography/computed tomography. We conducted review of the current literature at PubMed/MEDLINE until February 2020. The search language was English. The most widely used radiopharmaceuticals are the following:Experimental/pre-clinical approaches: (18)F-Misonidazole (18F-MISO) under clinical development, D(18)F-Fluoro-Methyl-Tyrosine (18F-FMT), 18F-FAMT (L-[3-18F] (18)F-Fluorothymidine (18F-FLT)), (18)F-Fluoro-Azomycin-Arabinoside (18F-FAZA), (68)Ga-Neomannosylated-Human-Serum-Albumin (68Ga-MSA) (23), (68)Ga-Tetraazacyclododecane (68Ga-DOTA) (as theranostic agent), (11)C-Methionine (11C-MET), 18F-FPDOPA, α In terms of lung cancer, positron emission tomography/computed tomography may have clinical application and utility (a) in personalizing treatment, (b) as a biomarker for the estimation of overall survival, disease free survival, and (c) apply a cost-effective patient approach because it reveals focuses of the disease, which are not found with the other imaging methods.
Identifiants
pubmed: 33062275
doi: 10.1177/2050312120961594
pii: 10.1177_2050312120961594
pmc: PMC7534078
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
2050312120961594Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
Eur J Nucl Med Mol Imaging. 2015 Apr;42(4):634-43
pubmed: 25573632
Ann Nucl Med. 2016 Apr;30(3):207-16
pubmed: 26661845
Ann Surg Oncol. 2015 Feb;22(2):636-41
pubmed: 25155392
Radiographics. 2018 Nov-Dec;38(7):2134-2149
pubmed: 30422775
J Nucl Med. 2014 Nov;55(11):1778-85
pubmed: 25256060
J Nucl Med. 2015 Feb;56(2):222-8
pubmed: 25593113
J Nucl Med. 2019 Jun;60(6):801-805
pubmed: 30954939
Expert Rev Respir Med. 2016;10(3):317-30
pubmed: 26822467
Clin Nucl Med. 2019 Jul;44(7):602-603
pubmed: 31021915
PET Clin. 2018 Jan;13(1):83-88
pubmed: 29157388
Curr Radiopharm. 2019 Dec 19;:
pubmed: 31858908
Curr Radiopharm. 2019 Dec 23;:
pubmed: 31868150
Nucl Med Biol. 2017 Jul;50:39-46
pubmed: 28456080
Cancer Sci. 2015 Nov;106(11):1554-60
pubmed: 26292100
BMJ. 2009 Jul 21;339:b2535
pubmed: 19622551
Lung Cancer. 2016 Apr;94:7-14
pubmed: 26973200
Clin Nucl Med. 2015 Mar;40(3):e183-9
pubmed: 25608152